Evidence map›Paper›PMID 41195268›Full record

ReviewFrontiers in oncology2025

Overcoming cancer drug resistance: insights into Apoptotic pathway modulation by plant-based nanoparticle and natural products.

Amit Kumar Singh, Prem Prakash Kushwaha, Ajaya Kumar Singh, Abhay K Pandey

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Amit Kumar SinghDepartment of Botany, BMK Govt. Girls College, Balod, India.
Prem Prakash KushwahaDepartment of Biological, Geological, and Environmental Sciences, Cleveland State University, Cleveland, OH, United States.
Ajaya Kumar SinghDepartments of Chemistry, Government VYT PG Autonomous College, Durg, India.
Abhay K PandeyDepartmentsof Biochemistry, University of Allahabad, Prayagraj, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is a complex progressive disease, characterized by uncontrolled cell growth, posing a serious global health problem across the population. The traditional treatments for this disease include chemotherapy, surgery, and radiation therapy, forming the backbone of care. However, over time, tumor cells often develop resistance to these treatments, making drug resistance a leading factor in disease progression and poor clinical outcomes for some patients. Cancer drug resistance is multifaceted at both the molecular and cellular levels. An important mechanism through which cancer cells acquire resistance to multiple drugs is dysregulated apoptosis (programmed cell death). This compromised apoptotic pathway resulted in prolongs cancer cell survival, accumulation of mutations that promote angiogenesis, stimulation of cell proliferation, impaired differentiation, and enhanced invasiveness during tumor progression. In the past few years, plant-derived natural products have garnered attention as promising therapeutic agents against drug-resistant cancers due to their minimal side effects and potent anticancer properties. However, their clinical application faces several challenges, including poor solubility, limited absorption, restricted tissue distribution, and rapid metabolism. An effective approach to address these limitations involves utilizing nanoparticles and nanomaterials, which can improve pharmacokinetics, enhance tumor-specific targeting, minimize side effects, and overcome drug resistance. This review delves into the fundamental molecular pathways associated with apoptosis and explores how phytochemicals and plant extracts, in combination with conventional drugs and plant-based nanoparticles can be utilized to treat cancer as well as cancer drug resistance by modulating its programmed cell death network.

Indexed as

apoptosiscancerdrug resistancenanoparticlenatural products

Identifiers

PMID41195268
PMCPMC12583045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.